Metsera has brought in over $500m in funding in just seven months as it looks to enter the competitive weight loss arena.

Lower Manhattan-based Metsera is one of the latest drug startups to throw its hat into the ring with the pharma giants ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Metsera, already a well-funded ...

Metsera is riding the wave of continued enthusiasm for GLP-1 drugs and its own early-stage data to bring in a hefty $215 ...

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...

NEW YORK--(BUSINESS WIRE)--Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced the close of a ...

The sizeable new round follows the announcement of phase 1 data for its lead asset MET-097i in September and, according to ...

New York-based Metsera, a biopharma developing medicines for obesity and metabolic diseases, has closed a $215 million Series ...

AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...

After a slow week last week, big rounds saw a good rebound with seven startups raising $100 million or more. While food ...